1-1, Doshomachi 4-chome
7 articles with Takeda Pharmaceuticals
Takeda Pharmaceutical Company Limited became the first private sector company to announce a financial commitment to the Global Fund’s Sixth Replenishment.
Takeda and London School of Hygiene & Tropical Medicine Establish "Takeda Chair in Global Child Health"
Takeda Pharmaceutical Company Limited and the London School of Hygiene & Tropical Medicine will announce at the evening reception, hosted by the Embassy of Japan in the United Kingdom, the establishment of the Takeda Chair in Global Child Health, endowed by a £3 million donation by Takeda to LSHTM.
Takeda to Highlight New Research into the Long-term Complications of Chronic Hypoparathyroidism at the European Congress of Endocrinology 2019 Annual Meeting
Seven presentations will be shared, including new data on the risks of long-term cardiovascular, renal and infection complications, underlining Takeda’s commitment to further understanding of this rare disease
Takeda Pharmaceutical Company Limited announced that it has entered into agreements to divest its Xiidra® 5% product to Novartis and its TachoSil® Fibrin Sealant Patch to Ethicon as part of its strategy to focus on business areas core to its long-term growth and facilitate rapid deleveraging following its acquisition of Shire.
Sixth pharma partner to internalize the Adimab platform
LegoChem Biosciences and Takeda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates in Immuno-Oncology
Takeda gains certain rights to LCB’s antibody-drug conjugate technology, ConjuAll, including LCB’s proprietary linker and conjugation platform, to research, develop and commercialize targeted immuno-oncology therapeutics.
Fears Nachawati Investigating Possible Uloric Lawsuits After FDA Issues Strongest Warning for Gout Drug
FDA orders boxed warning on packaging after studies confirm death risks